• Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us
NuShores BiosciencesNuShores Biosciences
  • Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us

NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock

March 31, 2022

Sam Monk — a seasoned medical device professional — will help to lead NuShores’ quality and regulatory efforts for NuCress™ bone regenerative product line.

Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Sam Monk has accepted the position of Regulatory and Quality Manager and will move to Little Rock from the Seattle area.   Mr. Monk will work closely with C-level management, research scientists, manufacturing, and our Quality and Regulatory team and services providers to mature NuShores’ bone and tissue regeneration product development efforts.  NuShores is currently working on several new medical devices based on our pipeline of UALR licenses and internally developed innovations and inventions.

According to Dr. Alex Biris, NuShores’ Co-founder and Chief Technical Officer, “Our team along with our experts found Mr. Sam Monk to be accomplished with business and new product development experience. He has been through the cycle of products from initial design through bench, and animal and clinicals, and post marketing. He has been through audits and direct FDA experience at multiple levels. Sam speaks the same language of regulatory sciences and his approach and philosophy towards working with FDA agrees with ours. He is a great addition to our team, and it will be my pleasure to work with him.”

Sam will report to NuShores’ CEO, Sharon Ballard.  “Sam shares our philosophy of quality at NuShores. We embrace quality as a personal value to provide extraordinary products and services to all stakeholders.  Sam will show us how to make quality a lifestyle at NuShores.  And he will work with our experts to finalize and submit our first medical device for consideration by the FDA for use in humans.  He has a reputation as a great teacher, and I cannot wait to learn from him,” shares CEO Ballard.

NuShores’ Mark Pelo, Manufacturing Manager, who has previously worked with Sam for several years at Medtronic, states that “Sam brings to NuShores all the tools required to establish and successfully guide, train, and support all our quality activities and to implement and accomplish our regulatory strategies and post-market responsibilities.  I’m excited to work with this seasoned professional again.”      

Sam brings over 30 years of medical device quality, design engineering and operations successes to NuShores.  His career positions include Principal Design Quality Engineer at Medtronic Neurological and Spine Division, and Senior Manager of Manufacturing Quality Operation at Philips Healthcare.  He also served as Senior Quality Engineer at Boston Scientific and Senior Quality Engineer and Assistant QA Manager for Welch Allyn. He has also served as a Quality Contractor with Sigma SOS for several years.

Sam shares that “I am honored to have this opportunity to participate in bringing to market this exciting and rather unique bone regeneration platform technology, and to join a team that has developed this groundbreaking medical device.  I look forward to applying my lessons learned and industry best practices to a brand-new quality management system.  I’m also excited to work with such a stellar collection of technical, manufacturing and regulatory specialists that NuShores has assembled.”

About NuShores Biosciences LLC

NuShores’ vision is to improve the quality of life for people globally and to compete successfully in the bone and tissue regenerative materials industry. Early studies suggest that NuShores’ licensed, patented technology could deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks and reducing healing times.  Research results show thatNuShores’ NuCress™ scaffold could offer a number of benefits that to date not achieved by currently marketed bone regeneration products, therefore promising to bring better treatment outcomes to millions of people with severe bone injuries. NuShores has the exclusive, global license from University of Arkansas Little Rock to commercialize university owned patented and patent-pending technologies. 

For more information about Sam Monk, visit https://www.linkedin.com/in/sam-monk-ab802b7/

For more NuShores information, visit https://nushores.com

Share

They’ve Said About US

  • The NuShores group has assembled a very strong development team under Dr. Biris and the operational depth needed to bring their novel materials to the market.  I am very excited to be contributing to NuShores and Alex’ team.

    Mike Douglas PhD
    Executive Director Texas Life Science Collaboration Center
  • I am honored to serve on the advisory board for NuShores Biosciences LLC. I look forward to opportunities to contribute to your efforts with my experience and lessons learned in the areas of science – technology planning and commercialization, and to assist in the clinical aspects to make it available to patients as soon as possible.

    C. Lowry Barnes MD
    Professor and The Carl L. Nelson, M.D. Distinguished Chair in Orthopaedic Surgery at UAMS
  • It is a rare opportunity to be able to support the historic scientific discoveries licensed to NuShores from UA Little Rock that will have a significant positive impact on public health and clinical practices.  I am blessed to be able to participate with NuShores team in maturing such scientific breakthroughs to commercial success

    Andrew G. Kumpuris
    Founder and Advisor
  • I am very excited to work with the team at NuShores in the development of an enabling technology in tissue regeneration.  I have worked with the group for some time now and have the greatest respect for their approach to the challenge and the quality of their research.  I believe that the rigor behind their work is world class and will be regarded as a new standard of care in repairing bone loss.

    Jeff Skiba PhD
    Founder of Vomaris Innovations Inc.
  • I am delighted to be working with such a wonderful team on lifechanging technologies and applications.  It is an honor to be along for the journey.

    James G. Wetrich
    Fellow of the American College of Healthcare Executives
  • I am pleased to serve on the NuShores’ Advisory Board and look forward to contributing to their venture’s product successes.  There is a need for their innovative NuCress™ bone void filler that has potential use in my areas of medical practice.  I look forward to working with the NuShores team in accomplishing the scientific, regulatory and development milestones to make such a product available to physicians and their patients

    James Y. Suen MD
    Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at University of Arkansas Medical Sciences
  • The opportunity to serve on the board of NuShores is exciting and thought-provoking.  As an active member of the scientific community with a specific interest in orthopedics, the ongoing research is especially relevant and exciting for me.  I am delighted to have to opportunity to help such a robust and creative group move their technology and research efforts forward

    Larry Suva PhD
    Professor and Department Head Texas A&M University

Contact Us

Send us a message at your convenience

Send Message

Search

Follow Us

  • LinkedIn

READ OUR FCOI

Contact Info

  • NuShores Biosciences LLC
  • 1523 South Bowman St. Suite 3-H, Little Rock, Arkansas 72211
  • 866-NUCRESS
  • info@nushores.com
  • nushores.com

In the News

  • NuShores receives additional funding for biomedical manufacturing automation to by US Army
  • NuShores Biosciences receives commercialization program funding for NuCress™ bone filler scaffolds
  • NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock

Awards


© 2025 —NuShores Biosciences LLC

Prev Next